NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT06894511 2026-04-08
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT06004661 2026-03-06
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Phase 2 Recruiting
NCT03042312 2021-03-24
RESIST-PC
Endocyte
Phase 2 Terminated